Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Exp Neurol. 2014 Oct 23;270:88–94. doi: 10.1016/j.expneurol.2014.10.008

Figure 2. Decremental responses in rsEMG in mSCS with fluoxetine treatment.

Figure 2

Left. Compound muscle action potentials (CMAP) recorded during repetitive stimulation (rsEMGs) in WT, untreated mSCS and mSCS treated with fluoxetine. Decremental responses were seen in mSCS while reduced decremental responses were shown in mSCS (εL269F) with fluoxetine treatment of 7.2 and 9.6µg/g. Middle. εL269F mice with 2.4 µg/g fluoxetine reduced decrement to 13.6±2.5% whereas decrement was 10.3±3.2% with 4.8 µg/g fluoxetine, 4.0±1.7% with 7.2 µg/g fluoxetine, and 2.8±1.0% with 9.6 µg/g treatment, compared with 19.7±2.3% in untreated εL269F mice. Right. To treated δS268F, decrement was 10.9±1.2% after 4.8 µg/g fluoxetine, 6.8±0.5% after 7.2 µg/g, and 4.2±0.6% after 9.6 µg/g treatment, compared with 18.8±3.1% in untreated δS268F mice. n=7; ***p<0.001, all comparisons were analyzed by Student’s t-test.